Skip to main content

Table 2 Overview of tumor responses

From: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model

Experiment Group CR (%) PR (%) Rats with metastases (%) n
1 Controla 0 0 0 7
RAD 5 mg/kga 0 0 0 6
177Lu-TATE 125 MBq 57 29 0 7
177Lu-TATE 278 MBq 71 29 0 7
RAD 5 mg/kg + 177Lu-TATE 125 MBq 29 57 71 7
RAD 5 mg/kg + 177Lu-TATE 278 MBq 14 57 86 7
2 Controlb 0 0 0 8
RAD 5.0 mg/kgb 0 13 75 8
RAD 2.5 mg/kgb 13 0 63 8
177Lu-TATE 125 MBqb 43 57 0 7
177Lu-TATE 125 MBq + RAD 5.0 mg/kgb 0 63 88 8
177Lu-TATE 125 MBq + RAD 2.5 mg/kgb 14 43 86 7
3 Controlb 50 0 0 8
RAD 4.5 weeksb 12.5 12.5 37.5 8
RAD 12 weeksb 12.5 25 50 8
177Lu-TATE 125 MBq + RAD 4.5 weeksb 87.5 12.5 12.5 8
177Lu-TATE 125 MBq + RAD 12 weeksb 75 25 25 8
  1. aRats did not survive until 42 to 146 days post start of treatment (p.t.), the time frame in which metastases became apparent in the other groups, because rats had to be euthanized when primary tumor size was >4 to 6 cm3. bPrimary tumors were surgically removed when tumor size was >4 to 6 cm3. CR, complete response (100% reduction of tumor size); PR, partial response (>50% reduction of tumor volume but no CR); n, number of animals/group; 177Lu-TATE, 177Lu-DOTA0, Tyr3-octreotate; RAD, RAD001.